tbuckley/cabot-search huggingface dataset:
93P Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Authors: D. Kotani, T. Yoshino, A.S. Paulson, T. Masuishi, H. Hochster, J. Krauss, Y. Sunakawa, A. Takashima, K. Yamazaki, H. Kawakami, T. Nishina, Y. Komatsu, T. Esaki, C. Eng, N.A. Dasari, Z. Yu, L. Chen, T. Yang, W. Schelman, T. Satoh
Journal: Annals of Oncology (2023)
109P Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Authors: None A.Pretta, P. Ziranu, E. Perissinotto, P. Ciracì, L. Giuliani, V. Pusceddu, M.C. De Grandis, A. Taravella, M. Puzzoni, V.M. Piva, C. Boccaccio, E. Lai, A.A. Prete, K. Cerma, F. Marmorino, R. Giampieri, S. Lonardi, C. Cremolini, F. Bergamo, M. Scartozzi
Journal: Annals of Oncology (2023)
103P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Authors: J. Wu, L. Zhu, C. Zhou, M. Shi, J. Chen, L. Zhao, Z. Han, C. Wang, J. Jiang, J. Yan, C. Wang, X. Wei, Y. Mao, X. Yang, Z. Qin, X. Tang, J. Zhang
Journal: Annals of Oncology (2023)
165P BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Authors: E. Amadeo, M. Persano, T. Tada, G. Suda, S. Shimose, M. Kudo, C. Yoo, F. Rossari, F. Vitiello, A. Casadei Gardini, M. Rimini
Journal: Annals of Oncology (2023)
148P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Authors: T. Kuzuya, T. Yamashita, T. Takehara, H. Aikata, N. Kato, Y. Hiasa, S. Nakamura, N. Morimoto, M. Moriguchi, M. Ikeda, J. Inoue, J. Tani, Y. Ueno, K. Chayama, R. Tateishi, Y. Kawamura, J. Furuse, M. Kudo, K. Yamamoto, N. Kokudo
Journal: Annals of Oncology (2023)

Atezo + Bev has been approved as first-line treatment in pts with uHCC based on a global phase 3 study (IMbrave 150). However, real-world data is lacking worldwide. Thus, we conducted the ELIXIR study to evaluate the safety and efficacy of Atezo + Bev prospectively in real-world Japanese pts. Here, we report the safety assessment and preliminary efficacy results in 493 pts out of 510 pts. In this prospective, multicenter, observational study, 510 systemic treatment-naïve pts with uHCC and Child-Pugh A received Atezo 1200 mg IV q3w + Bev 15 mg/kg IV q3w. The primary endpoint was adverse events of special interest (AESI). Efficacy outcomes were also assessed, including progression-free survival (PFS) and objective response rate (ORR). A total of 510 pts were enrolled between Apr 2021 and Feb 2022. 493 pts were analyzed and the median follow-up time was 14.5 mo (95% CI, 13.8, 15.0). A total of 240 (48.7%) AESIs and 149 (30.2%) Grade ≥3 AESIs were observed (Table). Median PFS was 8.1 mo (95% CI, 7.4, 9.5) per RECIST 1.1 and 8.3 mo (95% CI, 7.5, 9.7) per modified RECIST (mRECIST). ORR was 28.6% (95% CI, 24.6, 32.8) per RECIST 1.1 and 36.5% (95% CI, 32.3, 40.9) per mRECIST.Table: 148PAdverse events of special interestItemsAtezo + bev (n=493)AESIs all, n (%)240 (48.7)AESIs grade ≥3, n (%)149 (30.2)≥ 5% AESIs, n (%)Hepatic function disorder71 (14.4)Hypertension grade ≥368 (13.8)Endocrine diseases64 (13.0)Proteinuria grade ≥343 (8.7) Open table in a new tab In this analysis, as previously reported, additional safety signals were not observed in Japanese pts. The efficacy seen in ELIXIR was consistent with that of IMbrave150, and Atezo+Bev could be a standard first-line therapy for Japanese uHCC pts in the real world.
27P The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Authors: A. Tsuruga, M. Hosonuma, A. Sasaki, H. Isobe, N. Parinyanitikul, G. Gong, H.J. Lee, R. Yoshida, N. Hayashi, S. Nakamura, R. Seitz, D. Hout, N.T. Ueno, H. Masuda
Journal: Annals of Oncology (2023)
118P Non-invasive plasma cell-free 5-hydroxymethylcytosine as promising biomarkers for early diagnosing gastrointestinal cancers
Authors: Y. Wang, M. Liu, X. Hu, H. Wen, X. Gong, W. Ye, X. Yan, Z. Chen, S. Zhong, S. Zhou, X. Wang, Z. Lu, H. Xiu, A. Xu
Journal: Annals of Oncology (2023)
66P Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Authors: J. Zhang, Z. Liu, H. Ding, L. Ma, H. Lu, Y. Shi, F. Lin, L. Zheng, M. Wang, G. Qiao, Z. Deng, L. Yu, Y. Zhang, Y. Yuan, H. Lin
Journal: Annals of Oncology (2023)
67P Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Authors: K. Mohan, A. Prajapati, R.K. Kothari, S. Mondal, S. R, R. Nagarkar, S.B. Kane, A. Santa, D. Dadke
Journal: Annals of Oncology (2023)
208O Asian subgroup analysis of the THOR phase III study: Erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer and selected fibroblast growth factor receptor alterations
Authors: N. Matsubara, Y. Loriot, E.F. Burgess, S.H. Park, R.A. Huddart, J.H. Ku, B. Tran, S. Triantos, K. Deprince, S. Mukhopadhyay, R. Hemaya, J. Zhuo, A.O. Siefker-Radtke
Journal: Annals of Oncology (2023)
157P T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Authors: D.Y.Y. Peh, K. Chen, T.S.K. Ong, E.X. Yeo, F.N.N. Moe, D.C.E. Ng, K. Loke, S.X. Yan, S.P. Thang, A. Tong, H.L.H. Huang, B.M. Magsombol, R.H.G. Lo, A. Gogna, N.K.K. Venkatanarasimha, C.W. Too, S. Chandramohan, K.D. Zhuang, P. Chow
Journal: Annals of Oncology (2023)
170P Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Authors: F. Vitiello, M. Rimini, M. Persano, G. Suda, S. Shimose, F. Finkelmeier, G. Masi, F. Rossari, E. Amadeo, A. Casadei Gardini, T. Tada, M. Kudo, J. Cheon, H.Y. Lim, C. Yoo
Journal: Annals of Oncology (2023)
621P Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Authors: T. Yang, N. Wang, X. Zhu, M. Wang, L. Yao, Z. Fan, X. Sun, M. Pan, L. Zhang, Q. You, J. Xu, Y. Xu, H. Lu, B. li, G. Wang, S. Cai, F. Shen, G. Lv
Journal: Annals of Oncology (2023)
43P Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Authors: M. Wijaya, S.J. Haryono, F. Aldila, S.G. Tanu, J. Audrienna, B. Rabbani, K.N. Ramanto, A. Fajarrahman, S.S.M. Hasan, S. Sormin, F.A. Agatha, K.I. Junusmin, M. Amelia, J. Haruman, L. Sani, E. Fernandez, A. Irwanto, A. Salim, A. Winata, S. Ali
Journal: Annals of Oncology (2023)
132MO Zanidatamab (ZW25; Zani) in patients (pts) with previously treated advanced human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC): Asia subgroup analysis of the phase IIb HERIZON-BTC-01 study
Authors: H. Sun, J.W. Kim, H.J. Choi, H-M. Chang, L. Bao, J. Ying, F. Xie, M.A. Lee, K. Dong Uk, T. Song, H. Pan, G. Yu, K. Li, Q. Yan, X. Wu, Y. Bao, P. Garfin, J. Ma, J. Fan, D-Y. Oh
Journal: Annals of Oncology (2023)
135MO Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Authors: J.A. Ajani, F. Lordick, Y-J. Bang, P.C. Enzinger, D.H. Ilson, M.A. Shah, E. van Cutsem, R-H. Xu, G. Aprile, J. Xu, R.A. Pazo Cid, Y-K. Kang, J. Yang, D. Moran, P. Bhattacharya, M. Matsangou, A. Arozullah, J.W. Park, K. Shitara
Journal: Annals of Oncology (2023)
105P A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Authors: W. Guo, F. Bi, J. Dong, C. Jin, Z. Niu, Y. Wang, M. Sun, T. Wang, D. Yu, Y. He, R. Zhang, X. Yin, W. Feng, M. Zhang, L. Li, B. Zhang, X. Kang
Journal: Annals of Oncology (2023)
23P Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Authors: S.C. Lee, Y.H. Park, C. Singer, J. Balmaña, R.A. Dent, V.K. Tan, N.A.M. Sari, M. Md Yusof, F.V.F. Que, Y-S. Lu, N. Parinyanitikul, C.P. Pham, N.A.M. Taib, S-Y. Kong, Y. Antill, H.J. Kim
Journal: Annals of Oncology (2023)
153P IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Authors: M. Kudo, T. Yamashita, R.S. Finn, P.R. Galle, M.P. Ducreux, A-L. Cheng, K. Tsuchiya, N. Sakamoto, S. Hige, R. Take, K. Yamada, T. Asakawa, Y. Nakagawa, M. Ikeda
Journal: Annals of Oncology (2023)
126P From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Authors: V. Pusceddu, A. Pretta, V. Palma, M. Dettori, P. Ziranu, E. Palmas, G. Moledda, G. Sanna, C. Codipietro, C. Donisi, D. Rizzo, A.P. D'Agata, F. Balconi, S. Mariani, E. Lai, M. Puzzoni, L. Mascia, G. Santabarbara, M. Scartozzi
Journal: Annals of Oncology (2023)
179P The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Authors: Y. Ushimaru, R. Kawabata, T. Takeoka, A. Kitagawa, N. Ohara, H. Tomihara, S. Maeda, M. Imazato, S. Noura, A. Miyamoto
Journal: Annals of Oncology (2023)
149P A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Authors: Y. Narita, A. Komori, S. Hironaka, H. Kawakami, M. Furuta, T. Kawakami, A. Makiyama, K. Sugiyama, N. Takegawa, H. Hirano, T. Ando, T. Matsushima, A. Chida, T. Kashiwada, M. Komoda, T. Matsumoto, H. Oda, H. Yabusaki, K. Yoshimura, K. Muro
Journal: Annals of Oncology (2023)
76MO Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas
Authors: T.W-W. Chen, R. Sanfilippo, R.L. Jones, S.M. Schuetze, A. Sebio Garcia, R.M. Alvarez, N. Bui, J-H. Ahn, H.H.F. Loong, C-C. Yen, J.Y. Hong, H.S. Kim, S. Patel, R.P. Bryce, F. Xu, B. Zhang, N.V. Shah, R.C. Doebele, G. Schwartz, M. Gounder
Journal: Annals of Oncology (2023)

New treatments are needed for advanced dedifferentiated liposarcoma (DDLPS), which is characterized by MDM2 gene amplification. Milademetan is a selective, potent, small molecule inhibitor of the MDM2-p53 interaction that reactivates p53 to induce apoptosis of TP53 wild-type malignant cells. MANTRA (RAIN-3201; NCT04979442) is a global, randomized, multicenter, phase 3 study of milademetan vs. trabectedin in pretreated unresectable/metastatic DDLPS. Eligible pts: ≥18y; unresectable/metastatic DDLPS±WD; ≥1 prior systemic therapies (≥1 anthracycline regimen); radiographic evidence of PD ≤6m. Pts were randomized (1:1) to milademetan (260 mg orally QD d1–3 & d15–17 q28d) or trabectedin (1.5 mg/m2, 24-h iv infusion q3w) until PD or intolerability. Tumor response was evaluated at w8, 16, 24&32, then q12w. Primary endpoint: PFS by blinded independent central review (BICR). Secondary endpoints: OS; ORR; DCR; DOR; PFS by investigator; safety. Study sample size was estimated to support primary endpoint in favor of milademetan (HR 0.5, 94% power, type I error 0.05). Median age: 64y (range 20–82y); white (69.7%), male (56.6%). Median follow-up: 2.1m (range 0–13m). Median PFS by BICR was numerically but not significantly higher for milademetan. While immature, median OS was comparable in the two arms, as were ORR and DCR. Most common all grade and grade 3/4 TEAEs for milademetan (Table). No Grade 5 events occurred with milademetan vs. 5 with trabectedin. Dose reductions due to TEAEs were higher but discontinuation rates lower with milademetan.Table: 76MOStudy findingsEfficacy populationMilademetan (n=86)Trabectedin (n=89)Median PFS by BICR, m3.62.2HR=0.89 (95% CI 0.61–1.29; p=0.53)Median PFS by investigator, m3.72.1HR=0.80 (95% CI 0.55–1.15; p=0.22)Median OSa, months9.510.2HR=1.27 (95% CI 0.80–2.04; p=0.31)ORR, n (%)4 (4.7)3 (3.4) p=0.67DCR, n (%)29 (33.7)24 (27.0) p=0.33Safety populationn=86n=79Most common milademetan TEAEs, %NauseaThrombocytopeniaAnemia Vomiting70.961.644.244.258.225.336.719.0Most common grade 3/4 milademetan TEAEs, %ThrombocytopeniaNeutropeniaAnemia39.525.618.613.926.619.0TEAEs – fatal/grade 5, %06.3TEAEs leading to dose reductions, %44.229.1TEAEs leading to discontinuations, %11.619.0aPlanned interim analysis. Open table in a new tab aPlanned interim analysis. While median PFS was longer for milademetan, the difference was not significant. TEAEs were consistent with previous reports and manageable by dose interruptions/modifications. Further evaluation of milademetan is warranted in populations that may benefit from MDM2 inhibition.
90MO Panitumumab (PAN) vs bevacizumab (BEV) in metastatic colorectal cancer (mCRC) by microsatellite stable (MSS), RAS/BRAF, and HER2 amplification (HER2amp) status: Phase III PARADIGM biomarker study
Authors: T. Kato, K. Muro, J. Watanabe, K. Shitara, K. Yamazaki, H. Ohori, M. Shiozawa, H. Yasui, E. Oki, T. Sato, T. Naitoh, Y. Komatsu, J. Soeda, K. Yamamoto, R. Yamashita, K. Akagi, A. Ochiai, H. Uetake, K. Tsuchihara, T. Yoshino
Journal: Annals of Oncology (2023)
164P Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Authors: M-W. Kao, K-C. Hsieh, K-M. Rau, H-J. Ho, K-K. Huang, Y-H. Kuo, M-C. Hsieh
Journal: Annals of Oncology (2023)
70P Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Authors: K. Inoue, J. Ninomiya, K. Okubo, T. Nakakuma, H. Yamada, K. Kimizuka, T. Higuchi, T. Saito
Journal: Annals of Oncology (2023)
49P Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Authors: M.J. Shah, S. Rath, S. Gulia, P.G. Bhargava, A. Sekar, J. Bajpai, T. Shet, S. Desai, R. Sarin, R. Pathak, P. Popat, P. Parab, Y. Kembhavi, A. Patil, N.S. Nair, P. Rane, S. Joshi, R.A. Badwe, S. Gupta
Journal: Annals of Oncology (2023)
58P Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Authors: H. Iwata, Y. Naito, M. Hattori, A. Yoshimura, K. Yonemori, M. Aizawa, Y. Mori, J. Yoshimitsu, Y. Umeyama, T. Mukohara
Journal: Annals of Oncology (2023)
82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Authors: J. Choo, S. Nathan Jeraj, G. Chan, R. Sundar, W.P. Yong, M. Lee, N.Y.L. Ngoi, A. Wong, R.A. Soo, C.E. Chee, J. Lim, B-C. Goh, S.C. Lee, D.S. Tan
Journal: Annals of Oncology (2023)
134MO Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Authors: F. Lordick, M.A. Shah, K. Shitara, J.A. Ajani, Y-J. Bang, P.C. Enzinger, D.H. Ilson, E. van Cutsem, J. Gallego Plazas, J. Huang, L. Shen, S.C. Oh, P. Sunpaweravong, H.H.F. Soo, H.M. Türk, J.W. Park, D. Moran, P. Bhattacharya, Y.J. Cao, R-H. Xu
Journal: Annals of Oncology (2023)
62P Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Authors: M.A. Saleh, L. Kassem, A. Abdel Hafeez, P. Essam Eldin Shibel, M.A. Hassan, H.A. Azim
Journal: Annals of Oncology (2023)
113P Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Authors: K. Ou, X. Liu, X. Ma, L. Gao, Q. Wang, L. Yang
Journal: Annals of Oncology (2023)
130O The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Authors: S.Y. Rha, A. Kawazoe, Y. Bai, J. Xu, S. Lonardi, J-P. Metges, P.E. Yanez Weber, L.S. Wyrwicz, L. Shen, Y.V. Ostapenko, M. Bilici, H.C. Chung, K. Shitara, S. Qin, E. van Cutsem, J. Tabernero, K. Li, C-S. Shih, P. Bhagia, Y.Y. Janjigian
Journal: Annals of Oncology (2023)
146P Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Authors: K-W. Lee, Y-K. Kang, M-H. Chen, H. Hirano, Y. Sunakawa, S.T. Kim, C-C. Lin, W.P. Yong, T. Kawakami, T. Oshima, Z. Li, M. Hopkins, A. Levin, H. Wang, L. Goldstein, D. Zhou, S.Y. Rha
Journal: Annals of Oncology (2023)
106P Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Authors: Y. Yuan, Y. Deng, Y. Jin, Y. Pan, C. Wang, Z. Wang, Z. Zhang, X. Meng, Y. Hu, M. Zhao, H. Wang, N. Yang, D. Wu, X. Dong, D. Huang, M. Sun, L. Liu, D. Hua, Z. Guo, K. Ding
Journal: Annals of Oncology (2023)
77MO A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
Authors: X. Yu, J. Zhang, R. Liu, Y. Deng, Y. Cai, Y. Sun, Q. Dang, W. Hong, Z. Song, S. Guo, S. Gao, W. Su, M. Shi, S. Fan, B. Zhang, B. Pan, Y. Ren, J. Wang, C. Zhong, L. Ma
Journal: Annals of Oncology (2023)
LBA5 Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort
Authors: X. Hu, Q. Zhang, T. Sun, H. Xiong, W. Li, Y. Teng, Y-S. Lu, L-M. Tseng, M. Yan, H. Li, D. Pang, S.C. Chen, W. Chen, O. Jiang, J. Wang, X. Wu, E. Fan, L. Jiang, X. Zeng, N. Turner
Journal: Annals of Oncology (2023)
160P Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Authors: W. Kusano, S. Arita, M. Shimokawa, T. Otsuka, H. Shimokawa, J. Nakazawa, F. Koga, H. Oda, S. Takeshita, Y. Kawaguchi, H. Taguchi, T. Sakai, K. Nishikawa, S. Arima, Y. Ueda, M. Kawahira, T. Sakae, T. Shirakawa, T. Mizuta, K. Mitsugi
Journal: Annals of Oncology (2023)
22P Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Authors: H. Padmanabhan, N.T.T. Hassan, C.H. Yip, N.A.M. Taib, A.F. Abdul Aziz, M.W. Wong, W.K. Ho, B.H. Ang, V.Y.M. Lee, Y.Q. Lee, M-K. Thong, S.Y. Yoon, S-H. Teo
Journal: Annals of Oncology (2023)
35P Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Authors: W. Yeo, C.C.H. Kwok, T. Lau, K. Lai, L. Li, E. Leung, D. Chan, H. Wong, D. Lui, H. So, Y. Li, H. Yeo, E. Pang, F. Mo
Journal: Annals of Oncology (2023)
158P Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Authors: Y-Y. Su, M-Y. Lin, S.M. Cheng, W-L. Chang, C-M. Yeh, C-C. Yu, C-W. Hsu, Y-S. Shan, D-Y. Huang, L-T. Chen
Journal: Annals of Oncology (2023)
3MO Multimodal data fusion for improved risk stratification of breast cancer with multi-task 3D deep learning model: A multicenter study
Authors: W. Ren, Y. Yu, W. Ouyang, L. Mao, Q. Yao, Y. Tan, Z. He, T. Li, Z. Zhang, J. Wang, H. Yao
Journal: Annals of Oncology (2023)
54O Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC)
Authors: V.Y.M. Heong, F. Marmé, H.S. Rugo, S.M. Tolaney, A. Bardia, P. Schmid, W. Verret, T. Valdez, H. Wang, J. Cortes
Journal: Annals of Oncology (2023)
91MO Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study
Authors: Y. Kuboki, F. Pietrantonio, L. Salvatore, T. Esaki, D.P. Modest, D. Paez, J. Taieb, E. Ruiz, T.W. Kim, F.A. Meriggi, D. Cunningham, K-H. Yeh, E. Chan, J. Chao, N. Strydom, Y. Saportas, Q. Tran, C. Cremolini, M. Fakih
Journal: Annals of Oncology (2023)
136MO Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC): East Asia subgroup of FIGHT final analysis
Authors: Y-K. Kang, S. Qin, K-W. Lee, S.C. Oh, I-H. Kim, J.G. Kim, Y. Li, Z. Yan, J. Li, L-Y. Bai, C.P.K. Chan, A. Yusuf, A. Zahlten-Kuemeli, K. Taylor, K. Yamaguchi
Journal: Annals of Oncology (2023)
172P Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Authors: L. Shen, P. Chen, J. Lu, Y. Wan, Y. Zheng, F. Ye, J. Yang, Y. Liu, H. Pan, H. Chen, M. Sun, Q. Fan, Y. Yuan, K. Chen, Z. Sun, H. Tian, X. Ye, Z. Peng
Journal: Annals of Oncology (2023)
19P Referral patterns among breast cancer patients in county-level hospitals in China
Authors: P. Lu, Y. Ji, H. Qu, F. Zhou, J. Wang, Q. Wu, G. Dai, M. Liu, W. He, W. Liang, Q. Meng, Y. Ren, G. Luo, H. Wang, J. Luo, Z. Yu, G. Hu, J. Gao, Y. Zhang, C. Zhao
Journal: Annals of Oncology (2023)
171P Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Authors: K. Ueshima, N. Nishida, S. Hagihara, Y. Minami, H. Ida, M. Takita, H. Chishina, M. Morita, T. Aoki, M. Kudo
Journal: Annals of Oncology (2023)
601P Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Authors: X. Wu, Y. Mao, N. Xu, Y. Bai, D. Wang, X. Chen, X. Yin, Y. Deng, J. Yang, J. Zhang, J. Tang, Y. Huang, J. Li, M. Xu, N. Li, Y. Mao, A. Gozman, J. Xu
Journal: Annals of Oncology (2023)
156P Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Authors: J. Cheon, B-Y. Ryoo, H-D. Kim, K-P. Kim, M.H. Ryu, H.J. Chon, B. Kang, R.S. Finn, C. Yoo
Journal: Annals of Oncology (2023)
150P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Authors: J. Wu, C. Zhou, J. Yan, Z. Han, C. Wang, Z. Qin, J. Jiang, C. Wang, X. Tang, L. Zhu, J. Chen, Y. Mao, X. Wei, C. Shangguan, J. Zhang
Journal: Annals of Oncology (2023)